Unknown

Dataset Information

0

Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox.


ABSTRACT:

Background and aim

Hypozincemia is a prevalent adverse consequence in diabetes mellitus (DM) and β-Thalassemia patients. We aimed to evaluate the level of serum zinc in β-thalassemia patients with DM and a risk assessment for hypozincemia.

Methods

The study population included transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) with overt DM (fasting plasma glucose (FPG) ≥126 mg/dL, and/or 2-h plasma glucose≥200 mg/dL). Serum zinc concentration was measured by the colorimetric method, and the values below 70 μg/dL were defined as hypozincemia. Myocardial and liver T2*-weighted magnetic resonance imaging (MRI T2*, millisecond [ms]) were valued by a free contrast MRI. The demographic, clinical, paraclinical, and laboratory data were also recorded. The data belonged to the period from December 2018 until December 2020.

Results

Of 64 diabetic β-thalassemia patients, 41 cases had zinc data in their medical files (aged 38 ± 9 years, 48.8% female). 78.05% of patients (n = 32) were TDT, and 21.95% were NTDT (n = 9). The mean ± standard deviation of zinc level was 110.2 ± 127.6 μg/dL. The prevalence of hypozincemia was 9.76%, 95% confidence interval [CI] 0.27 to 19.24 (four cases). After controlling age, the odds of hypozincemia for using deferasirox (DFX) was 8.77, 95% CI 0.60 to 127.1. In β-thalassemia patients, the age-adjusted risk of hypozincemia was calculated at 15.85, 95% CI 0.47 to 529.3 for hepatitis C. The adjusted risk of hypozincemia based on age for antacid use was 6.34, 95% CI 0.39 to 102.7.

Conclusion

In light of this study, as well as hepatitis C, using DFX and antacids is associated with a high risk of hypozincemia amid diabetic β-thalassemia cases. However, upward bias should be taken into consideration.

SUBMITTER: Darvishi-Khezri H 

PROVIDER: S-EPMC10786396 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature

altmetric image

Publications

Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox.

Darvishi-Khezri Hadi H   Karami Hossein H   Naderisorki Mohammad M   Ghazaiean Mobin M   Kosaryan Mehrnoush M   Mosanejad-Galchali Amir A   Aliasgharian Aily A   Karami Hasan H  

PloS one 20240112 1


<h4>Background and aim</h4>Hypozincemia is a prevalent adverse consequence in diabetes mellitus (DM) and β-Thalassemia patients. We aimed to evaluate the level of serum zinc in β-thalassemia patients with DM and a risk assessment for hypozincemia.<h4>Methods</h4>The study population included transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) with overt DM (fasting plasma glucose (FPG) ≥126 mg/dL, and/or 2-h plasma glucose≥200 mg/dL). Serum zinc concentration  ...[more]

Similar Datasets

| S-EPMC4604499 | biostudies-literature
| S-EPMC3366648 | biostudies-literature
| S-EPMC4687615 | biostudies-other
| S-EPMC7419189 | biostudies-literature
| S-EPMC4599708 | biostudies-literature
| S-EPMC8706525 | biostudies-literature
| S-EPMC8733492 | biostudies-literature
| S-EPMC3945858 | biostudies-literature
| S-EPMC8781644 | biostudies-literature
| S-EPMC7367112 | biostudies-literature